Form 4 for MRNA Moderna
Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-14 · accession 0001127602-24-005355 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-16 | 2024-02-14 | MRNA | Bancel Stephane | CEO, Dir | A - Grant | $0.00 | +56.7K | 5.49M | +1% | $0 | |
| 2024-02-16 | 2024-02-16 | MRNA | Bancel Stephane | CEO, Dir | S - Sale | $88.88 | -26.4K | 5.46M | -0.5% | -$2.34M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-14 | A | A | 56,736 | $0.00 | 5,486,575 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-16 | S | D | 26,351 | $88.88 | 5,460,224 | D | — | — |